Qi Wei-Xiang, Cao Lu, Ou Dan, Li Shuyan, Xu Cheng, Cai Rong, Xu Haoping, Cai Gang, Chen Jiayi
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Proton-therapy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Front Oncol. 2024 Sep 13;14:1290852. doi: 10.3389/fonc.2024.1290852. eCollection 2024.
The purpose of this real-world study was to investigate the risk factors for developing recurrence among patients with pathological T1-3N0 breast cancer (BC) treated with breast-conserving surgery (BCS) followed by whole breast irradiation alone (WBI) and identify those clinically high-risk BCs who could benefit from regional nodal irradiation (RNI).
Female BC patients treated at Shanghai Ruijin hospital from 2009 to 2016 were retrospectively reviewed. The disease-free survival (DFS), breast cancer specific survival (BCSS) and overall survival (OS) were estimated by the Kaplan-Meier method, and survival differences were compared with the log-rank test. Univariate and multivariate analysis was performed using Cox proportional hazards regression analysis. An external validation was conducted by using SEER database.
A total of 622 BC patients treated with BCS+WBI alone were included. With a median follow-up of 82 months, the 7-year OS, BCSS and DFS for the entire cohort was 97%, 99% and 91%, respectively. Multivariable Cox analysis indicated that tumor size (=0.006), tumor location (=0.033), lymphovascular invasion (LVI) status (=0.0028) and Ki-67 index (=0.051) were independent risk factors for DFS. A scoring system was developed using these four factors and the 7-year DFS and OS were 97% and 96% for patients with 0-1 risk factors, 95% and 82% for patients with ≥2 risk factors (<0.0001 for DFS, and =0.0063 for OS). Based on tumor size and tumor location, an external validation by demonstrated that the 7-year OS was 90% and 88% for patients with 0-1 risk factor, which was significantly better than those defined as high-risk BC patients (82%, <0.0001).
By using our institute database, we establish a risk stratification system for identifying sub-group of pN0 BC patients, who are at high risk for developing recurrence. The results of our study support tailored RT decision-making according to individual risks, which needed to be confirmed in further studies.
本真实世界研究的目的是调查接受保乳手术(BCS)加单纯全乳照射(WBI)治疗的病理T1-3N0期乳腺癌(BC)患者复发的危险因素,并确定那些可能从区域淋巴结照射(RNI)中获益的临床高危BC患者。
回顾性分析2009年至2016年在上海瑞金医院接受治疗的女性BC患者。采用Kaplan-Meier法估计无病生存期(DFS)、乳腺癌特异性生存期(BCSS)和总生存期(OS),并通过对数秩检验比较生存差异。使用Cox比例风险回归分析进行单因素和多因素分析。利用SEER数据库进行外部验证。
共纳入622例仅接受BCS+WBI治疗方案的BC患者。中位随访82个月,整个队列的7年总生存率、乳腺癌特异性生存率和无病生存率分别为97%、99%和91%。多变量Cox分析表明,肿瘤大小(=0.006)、肿瘤位置(=0.033)、淋巴管侵犯(LVI)状态(=0.0028)和Ki-67指数(=0.051)是DFS的独立危险因素。利用这四个因素建立了一个评分系统,0-1个危险因素的患者7年DFS和OS分别为97%和96%,≥2个危险因素的患者为95%和82%(DFS<0.0001,OS=0.0063)。基于肿瘤大小和肿瘤位置的外部验证表明,0-1个危险因素的患者7年总生存率为90%和88%,显著优于定义为高危BC患者的生存率(82%,<0.0001)。
通过使用我院数据库,我们建立了一个风险分层系统,用于识别pN0期BC患者中复发风险高的亚组。我们的研究结果支持根据个体风险进行定制化放疗决策,这需要在进一步研究中得到证实。